Does Azacitidine Improve Survival in GVHD?
Azacitidine, a hypomethylating agent, shows promise in improving survival for patients with graft-versus-host disease (GVHD), particularly in steroid-refractory acute GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT). A phase 2 trial found a 6-month overall survival (OS) rate of 79% and 1-year OS of 59% in 25 patients treated with azacitidine (32 mg/m²/day for 5 days every 28 days), with complete or partial responses in 44%.[1] This outperformed historical controls, where steroid-refractory acute GVHD often has OS below 40%.
Real-world data supports these findings: A multicenter study of 162 patients with steroid-refractory acute GVHD reported median OS of 7.2 months and 1-year OS of 41%, with 54% achieving GVHD response.[2] Azacitidine also benefits chronic GVHD, reducing relapse risk via immunomodulation that preserves graft-versus-leukemia effects while controlling alloreactivity.[3]
How Does Azacitidine Work in GVHD?
It inhibits DNA methyltransferase, altering T-cell subsets (increasing regulatory T-cells, decreasing Th1/Th17 cells) and restoring hypomethylated gene expression in immune cells.[4] This targets GVHD pathogenesis without broad immunosuppression, explaining its activity in refractory cases.
What Do Clinical Trials Show for Acute vs. Chronic GVHD?
- Acute GVHD: Phase 2 data indicate 40-56% overall response rates (ORR), with median response duration of 3-6 months. A randomized trial (RELA trial) is ongoing to compare azacitidine plus ruxolitinib vs. ruxolitinib alone.[5]
- Chronic GVHD: Smaller series report 50-70% ORR, with 1-year OS around 70%. It serves as salvage after ibrutinib or ruxolitinib failure.[6]
No phase 3 trials confirm superiority yet, but consistent phase 2 and retrospective evidence points to survival gains over best available therapy.
Common Side Effects and Patient Risks
Main toxicities are reversible cytopenias (neutropenia in 50-70%, thrombocytopenia in 40%), nausea (30%), and infections (20-30% grade 3+).[1][2] No excess non-relapse mortality compared to controls. Patients with active infections or severe organ failure face higher risks.
How Does It Compare to Ruxolitinib or Other GVHD Treatments?
Azacitidine achieves similar ORR (40-60%) to ruxolitinib (55% in REACH2 trial) but may excel in post-JAKi failures.[7] Combinations (e.g., azacitidine + ruxolitinib) yield 70-80% responses in pilot studies.[5] Unlike steroids or ATG, it lowers relapse rates (10-20% vs. 30-40%).[3]
Current Guidelines and Availability
NCCN guidelines list azacitidine as a category 2B option for steroid-refractory acute/chronic GVHD.[8] It's FDA-approved for myelodysplastic syndromes but used off-label here. Generic versions are available, with no active U.S. patents blocking access (DrugPatentWatch.com).
[1] de Lima M, et al. Blood Adv. 2020
[2] Ghosh A, et al. Blood Adv. 2021
[3] Schroeder MA, et al. Biol Blood Marrow Transplant. 2019
[4] Hu B, et al. Front Immunol. 2022
[5] ClinicalTrials.gov: RELA Trial (NCT05203671)
[6] Dahi PB, et al. Bone Marrow Transplant. 2022
[7] Zeiser R, et al. NEJM. 2018 (REACH2)
[8] NCCN Guidelines: Cellular Therapies, 2023